Dyadic International, Inc. (DYAI)

Over the past six months, Dyadic International's stock price has declined. Key events impacting the stock include the Q2 2025 earnings report showing revenue growth but ongoing losses, a public offering of common stock, a strategic rebrand to Dyadic Applied BioSolutions, Q3 2025 financial results highlighting the commercial focus, amended convertible notes, expanded collaboration with Fermbox Bio, a commercial partnership for recombinant growth factors, a Nasdaq non-compliance notice, director equity transactions, a price target increase, and a decrease in short interest.

The provided information does not explicitly state a direct seasonality in demand for Dyadic International's products and services, but highlights increasing demand in certain markets that the company is targeting. The company is focused on high-growth non-therapeutic markets, suggesting a consistent and growing demand rather than a seasonal one.

Dyadic International, Inc., now operating as Dyadic Applied BioSolutions, is a biotechnology company focused on developing and commercializing fungal-based expression platforms, primarily its C1 and Dapibus™ systems, for the efficient production of proteins and enzymes across various sectors. The company operates within the Biotechnology industry, enabling cost-effective, high-yield manufacturing processes for biopharmaceuticals, industrial enzymes, agricultural bioactives, and biofuels.

Dyadic International, Inc. is headquartered in Jupiter, Florida, United States, and has research and commercial alliances in North America, Europe, and Asia. Production validation for RNase-Free DNase1 has been completed at a European CDMO partner.

In the past year, Dyadic International rebranded to Dyadic Applied BioSolutions, signaling a shift to a commercially focused enterprise. Analyst sentiment is generally "Hold," with MarketBeat's news sentiment rating for DYAI being "Very Positive News". Events affecting the company's reputation include the strategic rebranding, partnerships and milestones, product commercialization efforts, and a Nasdaq non-compliance notice.

Dyadic International, Inc. has 49 institutional owners and shareholders holding 27.95% of the stock. Major institutional owners include Apis Capital Advisors, LLC, and Vanguard Group Inc. Individual ownership accounts for 16.53% of shares outstanding, with Mark Emalfarb, the Founder, CEO, and Director, directly owning 13.35% of the company's shares.